Randomized phase II study of best available 5-FU versus low-dose Paclitaxiel in gastric cancer with peritoneal metastasis refractory to 5-FU containing regimen(JCOG0407)
Phase 2
- Conditions
- gastric neoplasm
- Registration Number
- JPRN-C000000138
- Lead Sponsor
- Japan Clinical Oncology Group(JCOG)
- Brief Summary
See the datails via "URL releasing results" above. Also the details can be seen in the JCOG website: http://www.jcog.jp/en/trials/index.html
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
(1) diabetes mellitus, uncontrolled or controlled with insulin (2) unstable angina, or myocardial infarction within 6 months prior to the study (3) arrhythmia, needing medical intervention (4) hypersensitivity to alcohol (5) HBs antigen or their HCV antibody are positive (6) massive pleural effusion (7) Grade 3-4 diarrhea (CTCAE ver3.0) (8) synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ (9) pregnant or lactating women (10) severe mental disease (11) not appropriate for the trial at the physician's assessment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method